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Abstract
No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We
report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant
gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old male patient with urothelial cancer
(transitional cell carcinoma) in the right kidney underwent three rounds of adjuvant gemcitabine-cisplatin che-
motherapy after extensive radical nephrectomy. However, he had new liver, lung metastases and synchronous two
separate primary colon cancer. The lung metastasis lesion was confirmed as a metastatic urothelial cancer via per-
cutaneous transthoracic needle biopsy (PTNB). Liver and lung metastasis lesions disappeared after the 4th cycle of
FOLFOX4 chemotherapy. In addition, colon cancer also disappeared after the 8th cycle of FOLFOX4 chemotherapy.
The patient was still showing a complete response after 4 months. Clinical trials using the FOLFOX regimen as sal-
vage therapy for gemcitabine-refractory advanced urothelial cancer are warranted.
Background
Most urothelial cancer develops from the urinary blad-
der, while urothelial cancer of the upper urinary tract is
uncommon, accounting for only 5 to 10% of all renal
tumours[1]. The standard therapy for urothelial cancer
is surgical resection, although cisplatin-based combina-
tion chemotherapy increases the survival in metastatic
advanced urothelial cancer [2-4]. Nevertheless, a com-
plete response is very rare, and most patients die within
2 years of diagnosis[5]. At present, the standard therapy
is gemcitabine-cisplatin combination therapy because
M-VAC (methotrexate, vinblastine, doxorubicin, cispla-
tin), which was previously the standard therapy, has a
mortality due to toxicity exceeding 3% [5-7]. No stan-
dard has been established for salvage therapy in gemci-
tabine-refractory advanced urothelial cancer, and many
ongoing clinical trials are examining new agents.
We report a complete response to FOLFOX-4 therapy
in a patient with metastatic urothelial cancer who devel-
oped lung metastases and an additional primary colon
cancer after a radical nephrectomy for urothelial cancer.
Case presentation
A 54-year-old male with urothelial cancer (transitional
cell carcinoma) was transferred to the hemato-oncology
department after the discovery of lung metastases.
Three months previously, he had undergone a radical
nephrectomy and hilar lymphadenectomy for a left kid-
ney mass, which was identified as invasive papillary
urothelial carcinoma, extending to the renal parench-
yma. The resection margin was free from carcinoma,
although there was metastatic carcinoma in one out of
two lymph nodes (pT3N3 M0) (Figure 1A). No meta-
static lesion was found on chest computed tomography
(CT) or on abdomen CT before surgery. Postoperatively,
he underwent three rounds of adjuvant chemotherapy
with gemcitabine (1000 mg/m
2 D 1 ,8 ,1 5 )a n dc i s p l a t i n
(75 mg/m
2 D1).
While performing a colonoscopy to investigate hema-
tochezia, a second primary cancer, an adenocarcinoma
of the colon, was discovered in the transverse (anal
verge 50 cm) and sigmoid (anal verge 20 cm) colon.
The level of carcinoembryonic antigen (CEA) was nor-
mal, and abdominal CT showed 1.7-cm wall thickening
in the sigmoid colon, but no measurable changes in the
transverse colon. Moreover, multiple lung metastases
were seen on chest CT (Figure 2A, 2C). A lung
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any medium, provided the original work is properly cited.metastasis was confirmed to be urothelial cancer after a
percutaneous transthoracic needle biopsy (Figure 1B)
performed on a left lower lobe posterior segment meta-
static lesion. The patient underwent FOLFOX-4 (oxali-
platin 85 mg/m
2 IV over 2 hours D1; leucovorin 200
mg/m
2 over 2 hrs, D1, 2; 5-fluorouracil (5-FU) 400 mg/
m
2 IV bolus, and 5-FU 600 mg/m
2 I Vo v e r2 2h r sa sa
continuous infusion repeated every 2 weeks) for colon
cancer and metastatic urothelial cancer, because he
refused surgery for the colon cancer. After four rounds
of chemotherapy, the lung metastases all disappeared,
except one fibrotic cavitary lung lesion (Figure 2B, 2D).
There was no hematologic or non-hematologic toxicity
other than mild grade 1 nausea, and no delayed treat-
ment schedule. Abdominal and chest CT performed
after eight rounds of chemotherapy still showed no
metastatic lesions, and positron emission tomography-
computed tomography (PET-CT) showed no metastatic
lesion (Figure 3A), with no
18F- fluoro-2-deoxyglucose
(FDG) uptake in the fibrotic cavitary lesion in the lung
(Figure 3B). In addition, CR of the colon cancer seen in
the transverse and descending colon was also confirmed
by colonoscopy and PET-CT after eight rounds of che-
motherapy. Nevertheless, regional radiotherapy and res-
cue chemotherapy are being considered because of
enlargement of a left para-aortic lymph node seen on
abdominal and chest CT after the twelve rounds of
FOLFOX chemotherapy. Therefore complete response
was maintained for four months, from after four rounds
(11/2008) until twelve rounds (3/2009) of FOLFOX
chemotherapy.
Discussion
For the last 15 years, M-VAC chemotherapy was used to
treat metastatic or advanced urothelial cancer, and gave
a tumor response of 50~70% with increased survival in
15~20% of patients[2,8,9]. However, the reported mor-
tality related to therapy exceeded 3%, and 25% of the
patients developed neutropenic sepsis, so its use was
limited to young patients or those with good general
performance[10]. Gemcitabine was reported to give a
good response in urothelial cancer and has low toxicity
[7]. Finally, a phase III study of gemcitabine-cisplatin
Figure 1 A: The pelvocalyceal tumor of the kidney reveals high-grade urothelial carcinoma (H&E, ×100). B:P T N Bf r o ml u n gs h o w s
metastatic urothelial carcinoma (H&E, ×200).
Figure 2 A, B: Chest CT demonstrating hematogenous
metastastatic nodule in RML (arrow, A) disappeared after 4
th
FOLFOX4 cycles (B). C, D: Chest CT demonstrating hematogenous
metastastatic nodule in LLL (arrow, C) that formed fibrotic cavity
after 4
th FOLFOX4 cycles (D).
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pared with M-VAC, but lower toxicity and better safety.
Consequently, G-C is now used widely to treat urothe-
lial cancer[5]. Unfortunately, the tumor recurs in most
patients within one year[9,10], necessitating secondary
therapy after the failure of standard therapy. Although
many ongoing clinical trials are examining this, no treat-
ment has been established as secondary therapy after
failure of G-C or M-VAC chemotherapy.
Oxaliplatin is more potent than cisplatin in vitro and has
shown efficacy in preclinical studies against many tumor
cell lines[11,12]. It has also proved efficacious in several
phase II trials and is considered less nephrotoxic than cis-
platin and causes less bone marrow suppression than car-
boplatin[10,13,14]. However, the activity of an oxaliplatin
single regimen for urothelial cell cancer was minimal in
phase II studies by Moore et al.[13] and Winquist et al.
[14]. Therefore, we suggest that our case of TCC showed a
complete response due to synergistic effects of FOLFOX-
4, rather than to those of oxaliplatin as a single drug. The
efficacy of 5-FU and leucovorin combination therapy for
colorectal cancer is widely known[15,16]. The efficacy of
5-FU in advanced urothelial cancer is unclear, but a review
of published studies in 1987 described response rates of
about 15% using unmodulated single agent 5-FU[17]. In
combination with alpha interferon, a partial response rate
of 30% was obtained[18]. Recently, a phase II trial of con-
tinuous 5-FU infusion showed a median progression-free
survival of 1.9 months and a median overall survival of 6.5
months[19].
The FOLFOX regimen, which is a combination of 5-
FU, leucovorin, and oxaliplatin, can involve various
doses and schedules. It shows low toxicity and good effi-
cacy for colon cancer and stomach cancer, so it is used
widely at present. The addition of new agents such as
bevacizumab is expected to increase the complete
response and survival rates for patients with metastatic
colorectal cancer [20,21]. There are few reports of FOL-
FOX therapy for urothelial cancer, only a phase II trial
by Lorenzo et al., published in 2004. They used FOL-
FOX-4 in 18 patients who had previously been treated
for urothelial cancer, and reported only low-grade toxi-
city and a 19% overall response rate, all partial
responses[22].
Our patient was given FOLFOX therapy because the
urothelial cancer failed to respond to G-C combination
therapy, as metastases were discovered and there was an
accompanying second primary colon cancer. He showed
ac o m p l e t er e s p o n s ei nb o t ht he metastatic urothelial
cancer and colon cancer. In addition to the ongoing
clinical studies of gallium nitrate, ifosfamide, peme-
trexed, vinflunine, and molecular targeting agents, a
clinical trial of FOLFOX-4 therapy for urothelial cancer
seems to be warranted[23].
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